Texas Permanent School Fund Acquires 586 Shares of uniQure (NASDAQ:QURE)

Texas Permanent School Fund grew its holdings in uniQure (NASDAQ:QUREGet Rating) by 2.3% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 26,142 shares of the biotechnology company’s stock after purchasing an additional 586 shares during the quarter. Texas Permanent School Fund owned approximately 0.06% of uniQure worth $487,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Meeder Asset Management Inc. grew its position in shares of uniQure by 128.5% in the 2nd quarter. Meeder Asset Management Inc. now owns 3,457 shares of the biotechnology company’s stock worth $64,000 after buying an additional 1,944 shares during the last quarter. Banque Pictet & Cie SA grew its position in shares of uniQure by 41.6% in the 2nd quarter. Banque Pictet & Cie SA now owns 111,946 shares of the biotechnology company’s stock worth $2,087,000 after buying an additional 32,905 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of uniQure by 25.4% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 186,669 shares of the biotechnology company’s stock worth $3,480,000 after buying an additional 37,771 shares during the last quarter. Granite Point Capital Management L.P. purchased a new position in shares of uniQure in the 2nd quarter worth approximately $1,118,000. Finally, Los Angeles Capital Management LLC grew its position in shares of uniQure by 30.8% in the 2nd quarter. Los Angeles Capital Management LLC now owns 34,409 shares of the biotechnology company’s stock worth $641,000 after buying an additional 8,099 shares during the last quarter. Institutional investors own 86.46% of the company’s stock.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $23.00 on Wednesday. The company has a current ratio of 7.26, a quick ratio of 7.20 and a debt-to-equity ratio of 0.24. uniQure has a 12 month low of $12.52 and a 12 month high of $30.41. The company has a 50 day simple moving average of $19.51 and a two-hundred day simple moving average of $19.03. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -8.55 and a beta of 0.96.

Insider Buying and Selling at uniQure

In other uniQure news, VP Alexander Edward Kuta III sold 2,306 shares of uniQure stock in a transaction that occurred on Wednesday, September 21st. The shares were sold at an average price of $18.65, for a total transaction of $43,006.90. Following the completion of the sale, the vice president now directly owns 92,890 shares in the company, valued at approximately $1,732,398.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 3.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on QURE. The Goldman Sachs Group cut their price objective on shares of uniQure from $54.00 to $48.00 and set a “buy” rating on the stock in a research report on Thursday, November 3rd. StockNews.com assumed coverage on shares of uniQure in a research report on Wednesday, October 12th. They issued a “sell” rating on the stock. TheStreet downgraded shares of uniQure from a “c-” rating to a “d” rating in a research report on Tuesday, August 9th. Wells Fargo & Company dropped their target price on shares of uniQure from $34.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of uniQure in a research report on Thursday, November 3rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, uniQure currently has an average rating of “Moderate Buy” and an average target price of $45.43.

About uniQure

(Get Rating)

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis.

Featured Articles

Want to see what other hedge funds are holding QURE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for uniQure (NASDAQ:QUREGet Rating).

Institutional Ownership by Quarter for uniQure (NASDAQ:QURE)

Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.